# COVAXX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/covaxx

- Industry: Biotechnology
- Headquarters: US
- Website: www.covaxx.com
- Latest round: Seed (Mar 25, 2020)
- Investors on record: 1

## About

COVAXX is a biopharmaceutical company focused on developing innovative immunotherapeutic products targeting neurological diseases, particularly through peptide-based vaccines aimed at enhancing immune responses.COVAXX is dedicated to creating immunotherapeutic products that target neurological conditions. The company was founded by Lou Reese, Max Fox, Mei Hu, and Peter Diamandis. Mei Hu currently serves as the CEO. COVAXX is based in the United States and has engaged in a funding round on March 25, 2020, to further its initiatives. The total number of deals recorded for COVAXX is 1.COVAXX specializes in developing and commercializing immunotherapeutic products, focusing primarily on treating neurological diseases with peptide-based vaccines. These vaccines stimulate the immune system to combat conditions like Alzheimer’s disease, aiming to improve patient outcomes. COVAXX markets its products to healthcare providers, research institutions, and pharmaceutical companies, particularly in North America and Europe where demand for advanced neurology solutions is high.COVAXX generates revenue by collaborating with research institutions and pharmaceutical companies through B2B transactions, primarily via joint development agreements. Revenue streams include milestone payments, licensing fees, and royalties from future product sales, with a focus on integrating their peptide-based vaccines in treatment plans offered by healthcare providers, facilitating the development-to-application process.COVAXX plans to leverage its recent funding from the Seed round in March 2020 to advance the development of new products targeting neurological diseases. Additionally, the company aims to expand into European markets and increase its presence in North America by 2022. The funding will support the development of its novel peptide-based vaccines, enhancing its capacity to address unmet medical needs in neurology.

## Funding rounds

- Seed, Mar 25, 2020 — Prime Movers Lab

## Investors

- Prime Movers Lab (https://capitalatlas.ai/funds/prime-movers-lab) — Seed